THE 7TH INTERNATIONAL CONGRESS OF BMT 2023 28TH ANNUAL CONGRESS OF KSBMT

Exploring New Insights into the Future of HSCT and Cellular Therapy AUGUST 31(Thu) – SEPTEMBER 2(Sat), 2023 BUSAN, KOREA / OFFLINE CONGRESS http://icbmt.or.kr

Name	Professor Geoffrey Hill, MD, FRACP,	
	FRCPA	
	Senior VP and Director, Translational	1000
Current Position	Science and Therapeutics Division, Fred	
	Hutchinson Cancer Center	
Country	USA	A TIE
Major Field	GVHD & Immunology	

Educational Background

Geoff Hill is a medical graduate of the University of Auckland and Hematologist, training in New Zealand and The Dana Farber Cancer Institute in Boston. He was PI of a transplant immunology laboratory in Brisbane, Australia between 2001 and 2018 which focused on the interactions between cytokines, antigen presenting cells and T cell differentiation during stem cell transplantation. His laboratory developed a number of paradigms in the field that have instructed clinical practice over this period.

Professional Experience

Prof. Hill moved to The Fred Hutchinson Cancer Center (Fred Hutch) in Seattle, USA in 2018 to take up the Jose Carreras/E. Donnall Thomas Endowed Chair for Cancer Research and Director roles for Hematopoietic Stem Cell Transplantation and the Immunotherapy Integrated Research Center. In 2022, he also became Senior Vice President and the Head of the newly formed Translational Science and Therapeutics Division. During his tenure with Fred Hutch, his laboratory has developed new multiome and imaging approaches to study aberrant and tumor-specific immune responses in tissue that have led to a number of new NIH R01, U01 and P01 funded preclinical and translational clinical studies.

Other Experience and Professional Memberships

- 1991- Royal Australasian College of Physicians
- 1993- Royal College of Pathologists of Australasia
- 1993- Transplantation Society of Australia and New Zealand
- 1993- Hematology Society of Australia and New Zealand
- 1993- International Society for Hematology and Graft Engineering
- 2002- Australian Society of Immunology
- 2003- Australian Society of Bone Marrow Transplantation
- 2003- American Society of Hematology
- 2003- American Association of Immunology
- 2003- American Society of Bone Marrow Transplantation
- 2022- American Association of Physicians

Main Scientific Publications

ICBMT 2023 Secretariat [People-x.,Inc]

1F, Haeoreum B/D 16, Yeoksam-ro 17 gil, Gangnarn-gu, Seoul, 06246, Korea T. +82-2-566-6031 F. +82-2-566-6087 E. icbmt@icbmt.or.kr

1.+82-2-566-6031 F.+82-2-566-6087 E. ICDMT@ICDMT.0F.KF

The Korean Society of Blood and Marrow Transplantation KSBMT

- Hill GR, Crawford JM, Cooke KR, et al. Total body irradiation and acute graft-versus-host disease. The role of gastrointestinal damage and inflammatory cytokines. <u>Blood</u> 1997; 90:3204-3213. PMID: 9376604
- Hill GR, Olver SO, Kuns RD et al., MacDonald KP. Stem cell mobilization with G-CSF induces type-17 differentiation and promotes scleroderma. <u>Blood</u> 2010, 116(5):819-28. PMID: 20435882.
- Koyama M, Kuns RD, Olver SD, et al., Hill GR. Recipient nonhematopoietic antigenpresenting cells are sufficient to induce lethal acute graft-versus-host disease. <u>Nat Med</u> 2012;18:135-142. PMID: 22127134
- Alexander KA, Flynn R, Lineburg KE et al., Hill GR & MacDonald KP. CSF-1-dependant Bone Marrow Derived Macrophages Mediate Chronic Graft-Versus-Host Disease. <u>J Clin</u> <u>Invest.</u> 2014; 124(10):4266-80. PMID: 25157821.
- Koyama M, Mukhopadhyay P, Schuster I, et al., Hill GR. MHC class II antigen presentation by the intestinal epithelium initiates graft-versus-host disease and is influenced by the microbiota. <u>Immunity</u> 2019; 51:885-898. PMC6959419.
- Martins JP, Andoniou CE, Fleming P, Kuns RD, Daly S, Schuster IS, Varelias A, Tey SK, Degli-Esposti MA*, Hill GR*. Strain-specific antibody therapy prevents cytomegalovirus reactivation after transplantation. <u>Science</u> 2019; 363:288-293. (*denotes equal contribution) PMID: 30655443.
- 7. Vuckovic S, Minnie S, Smith D, et al., **Hill GR**. Bone marrow transplantation generates T cell-dependent myeloma control in mice. *J Clin Invest.* 2019; 129:106-121. PMC6307976.
- Minnie SA, Waltner OG, Ensbey KS., et al Hill GR. Depletion of exhausted alloreactive T cells enables targeting of stem like memory T cells to generate tumor-specific immunity. Science Immunology. 2022, Oct 21;7(76):eabo3420. PMID: 36240285.
- Minnie SA, Waltner OG, Ensbey KS, et al., Hill GR. Checkpoint inhibition with anti-TIGIT and lenalidomide provide synergistic anti-myeloma activity after SCT. <u>J Clin Invest</u>. 2023; Feb 15;133(4):e157907. PMID: 36512425.
- Koyama M, Hippe DS, Srinivasan S, et al., Hill GR. Intestinal Microbiota Controls Graftversus-Host Disease Independent of Donor-Host Genetic Disparity. <u>Immunity</u> 2023, Provisionally accepted 5/19/23

ICBMT 2023 Secretariat [People-x.,Inc] 1F, Haeoreum B/D 16, Yeoksam-ro 17 gil, Gangnam-gu, Seoul, 06246, Korea T. +82-2-566-6031 F. +82-2-566-6087 E. icbmt@icbmt.or.kr

The Korean Society of Blood and Marrow Transplantation KSBMT